#USA #Cambridge #ALS #NeuroSense #PrimeC

NeuroSense Therapeutics Provides Key Update on Clinical Development

On August 13, 2026, NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a clinical biotech company focused on innovative treatments for neurodegenerative diseases, released an informative letter from CEO Alon Ben-Noon to shareholders. The letter emphasized the company’s preparations for the pivotal Phase 3 PARAGON study, particularly targeting Amyotrophic Lateral Sclerosis (ALS).

Focus on the PARAGON Study

NeuroSense’s primary objective is to initiate the PARAGON study, which will involve around 300 participants. The FDA has approved NeuroSense to commence this trial, which is a significant milestone for the organization and patients alike.

Ben-Noon acknowledged that the large-scale requirements of the study necessitate substantial financial resources, and securing these funds has taken longer than expected. NeuroSense is actively exploring various avenues for financing, including partnerships with pharmaceutical companies, strategic investors, and non-dilutive funding sources such as grants.

With a focus on the quality of financing, the leadership team aims to secure resources that not only provide necessary funds but also contribute valuable industry insights and relationships that can bolster the development of PrimeC, the company’s lead product candidate.

Commitment from Leadership

In a notable display of confidence in the company's potential, both Ben-Noon and CFO Or Eisenberg made personal investments of $200,000 each, totaling $600,000. This investment reflects their strong belief in the future of NeuroSense and its mission to develop effective treatments for ALS.

Exploring Regulatory Opportunities

While the PARAGON study is a priority, NeuroSense sees potential opportunities to leverage existing clinical data to expedite PrimeC’s development in various territories. In Canada, the company is preparing a New Drug Submission (NDS) for PrimeC, with expectations to file in December 2026. By pursuing regulatory avenues sooner, NeuroSense aims to potentially help patients without the prolonged wait for the completion of the PARAGON study.

The ongoing discussions with Health Canada illustrate NeuroSense's commitment to navigating the complexities of the regulatory landscape efficiently to bring PrimeC to market, focusing on diseases that progress rapidly, such as ALS.

Strategic Partnerships and Compliance

Beyond financing, NeuroSense continues to explore strategic partnerships that could enhance the development and commercialization of PrimeC. The company is reviewing its portfolio and capabilities to create value for its stakeholders.

In terms of compliance, NeuroSense is adhering to the Nasdaq continued-listing requirements and is taking measures to address any deficiencies, which include possible reverse share splits to meet the minimum bid price requirement. The upcoming shareholder meeting will discuss strategies to maintain compliance with the Nasdaq exchange, which is critical for the company’s ongoing operations.

A Vision for the Future

NeuroSense's journey is filled with challenges, yet the work done thus far has paved several credible pathways for its future endeavors. The leadership team emphasizes executing the outlined strategies effectively and keeping stakeholders informed about progress.

Alon Ben-Noon concluded the letter by expressing gratitude for shareholders’ continued support and assured them that the team at NeuroSense is diligently committed to achieving the goals set forth in the company's strategic framework.

About NeuroSense Therapeutics

Founded to tackle severe neurodegenerative diseases, NeuroSense focuses on developing innovative therapies, with PrimeC targeting underlying biological mechanisms contributing to diseases like ALS. NeuroSense continues to report significant findings from its clinical trials, demonstrating meaningful advancements in treating neurological disorders. For further insights, visit the company's website and follow them on LinkedIn, YouTube, and X.